Noting that in 2017, GlaxoSmithKline withdrew the glucagon-like peptide 1 (GLP-1) receptor agonist albiglutide for commercial reasons, Adrian F. Hernandez, MD, from the Duke University School of ...

Albiglutide did not meet the noninferiority criteria (95% CI, 0.08% to 0.34%). Significant weight loss occurred in both groups, although liraglutide outperformed albiglutide (2.19 vs 0.64 kg).

Albiglutide (trade name Eperzan) has been approved since March 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control.

The GLP-1 agonist albiglutide reduces major CV events by 20% in type 2 diabetes patients with cardiovascular disease; GSK has ceased marketing the drug but say they will seek a new home for it.

Data from five long-term Phase III studies (Harmony 1 to 5) comparing albiglutide, an investigational glucagon-like peptide receptor agonist (GLP-1), to placebo and a range of active comparators ...

LONDON—GlaxoSmithKline PLC's diabetes treatment albiglutide was approved for use by U.S. regulators Tuesday, after a series of drug-development setbacks for the company. Albiglutide was approved ...

Albiglutide (TanzeumTM/Eperzan®) is a glucagon-like peptide-1 receptor agonist (GLP-1), a biological product for the treatment of type 2 diabetes, administered once-weekly using an injector pen ...

Albiglutide, a long-acting glucagon-like peptide-1 receptor agonist, reduces the risk of cardiovascular events among older adults with type 2 diabetes and cardiovascular disease, ...

Albiglutide is an investigational medicine which fuses human GLP-1 to human albumin. It is designed to have the potential to extended duration of action and allow for weekly or less-frequent ...

Phase 3 Trial Update of Albiglutide for Type 2 Diabetes. July 11, ...

Albiglutide (trade name Eperzan) has been approved since March 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control.

Albiglutide (trade name Eperzan) has been approved since March 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control. The German ...